Skip to main content
Hyam Levitsky, MD, Oncology, Baltimore, MD

HyamLevitskyMD

Oncology • Baltimore, MD

Physician

Join to view full profile

Dr. Levitsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Levitsky's full profile

Already have an account?

  • Office

    600 N Wolfe St
    Baltimore, MD 21287
    Phone+1 410-955-8964

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1988 - 1991
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1984 - 1987
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1984

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1987 - 2022
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2002

Publications & Presentations

PubMed

Press Mentions

  • As Allogeneic Cell Therapy Approaches Flourish, Century Loads up $160M to Scale iPSC Platform for CAR-T, CAR-NK
    As Allogeneic Cell Therapy Approaches Flourish, Century Loads up $160M to Scale iPSC Platform for CAR-T, CAR-NKMarch 3rd, 2021
  • Century Therapeutics Launches with USD 250M Financing for Induced Pluripotent Stem Cell (iPSC) Allogeneic Cell Therapy Platform
    Century Therapeutics Launches with USD 250M Financing for Induced Pluripotent Stem Cell (iPSC) Allogeneic Cell Therapy PlatformJuly 1st, 2019
  • Bayer Powers Versant Cell Therapy Startup to $250M Round
    Bayer Powers Versant Cell Therapy Startup to $250M RoundJuly 1st, 2019

Grant Support

  • Immunologic Targets In Myeloid LeukemiaNational Cancer Institute2010–2012
  • Non-Invasive Quantification Of Vaccine-Mediated Antigen Delivery ToNational Cancer Institute2010–2011
  • Regulatory T Cells In B Cell LymphomaNational Cancer Institute2008–2011
  • Human ImmunologyNational Cancer Institute2006–2010
  • Vaccination In Combination With Imatinib Mesylate For Chronic Myeloid LeukemiaNational Center For Research Resources2007
  • K562/GM-CSF VaccinationNational Center For Research Resources2005–2006
  • Cancer Vaccines In The Treatment Of CMLNational Cancer Institute2004–2005
  • Immunotherapy For B Cell LymphomaNational Cancer Institute2002
  • Tumor VaccinesNational Cancer Institute1997–2002
  • Tumor Induced Antigen Specific T Cell ToleranceNational Cancer Institute1998–2000
  • Vaccine Strategies To Enhance CD4+ T Cell PrimingNational Institute Of Allergy And Infectious Diseases1995–1998
  • Novel T Cell Subset--Nk1+ Alpha BetaNational Cancer Institute1994–1995
  • Strategies For Enhancing Antigen Specific ImmunityNational Institute Of Allergy And Infectious Diseases1994
  • Analysis Of A Novel T Cell Subset--Nk1+ Alpha BetaNational Cancer Institute1991–1993

Dr. Hyam Levitsky, Dr. Hyam Levitsky, MD, Dr. H Levitsky